Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
AYTU Stock Forecast 2025-2026
$1.25
Current Price
$7.71M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to AYTU Price Targets
+540.0%
To High Target of $8.00
+540.0%
To Median Target of $8.00
+540.0%
To Low Target of $8.00
AYTU Price Momentum
-3.8%
1 Week Change
+20.2%
1 Month Change
-61.8%
1 Year Change
-26.5%
Year-to-Date Change
-63.8%
From 52W High of $3.45
+31.6%
From 52W Low of $0.95
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Aytu BioScience (AYTU) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on AYTU and similar high-potential opportunities.
Latest AYTU Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, AYTU has a bullish consensus with a median price target of $8.00 (ranging from $8.00 to $8.00). Currently trading at $1.25, the median forecast implies a 540.0% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AYTU Analyst Ratings
1
Buy
0
Hold
0
Sell
AYTU Price Target Range
Low
$8.00
Average
$8.00
High
$8.00
Current: $1.25
Latest AYTU Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AYTU.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 9, 2023 | Maxim Group | Naz Rahman | Buy | Initiates | $5.00 |
| May 31, 2023 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $20.00 |
| Jul 21, 2022 | HC Wainwright & Co. | Vernon Bernardino | Buy | Maintains | $6.00 |
| May 17, 2022 | Cantor Fitzgerald | Jennifer Kim | Overweight | Maintains | $5.00 |
| Apr 28, 2022 | HC Wainwright & Co. | Vernon Bernardino | Buy | Maintains | $11.00 |
| Mar 30, 2021 | Cantor Fitzgerald | Overweight | Initiates | $0.00 | |
| Nov 25, 2020 | HC Wainwright & Co. | Buy | Initiates | $0.00 | |
| Nov 25, 2020 | Northland Securities | Outperform | Initiates | $0.00 | |
| May 29, 2020 | HC Wainwright & Co. | Buy | Initiates | $0.00 | |
| Oct 22, 2018 | Northland Securities | Outperform | Initiates | $0.00 |
Aytu Biopharma Inc. (AYTU) Competitors
The following stocks are similar to Aytu BioScience based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Aytu Biopharma Inc. (AYTU) Financial Data
Aytu Biopharma Inc. has a market capitalization of $7.71M with a P/E ratio of -0.4x. The company generates $77.23M in trailing twelve-month revenue with a -6.8% profit margin.
Revenue growth is -13.5% quarter-over-quarter, while maintaining an operating margin of -2.3% and return on equity of -22.7%.
Valuation Metrics
Market Cap
$7.71M
Enterprise Value
$4.45M
P/E Ratio
-0.4x
PEG Ratio
3.0x
Price/Sales
0.1x
Growth & Margins
Revenue Growth (YoY)
-13.5%
Gross Margin
+66.5%
Operating Margin
-2.3%
Net Margin
-6.8%
EPS Growth
-29.3%
Financial Health
Cash/Price Ratio
+264.5%
Current Ratio
1.0x
Debt/Equity
55.7x
ROE
-22.7%
ROA
-2.5%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Aytu Biopharma Inc. (AYTU) Business Model
About Aytu Biopharma Inc.
What They Do
Develops specialized prescription therapeutics for various medical needs.
Business Model
Aytu Biopharma generates revenue by producing and commercializing a diverse range of prescription therapeutics, primarily targeting pediatric conditions and other niche markets like urology and orthopedics. The company invests in clinical trials to enhance its product pipeline and engages in strategic partnerships and acquisitions to expand its market presence.
Additional Information
Headquartered in Englewood, Colorado, Aytu Biopharma is committed to innovation in the biotechnology sector and aims to improve healthcare outcomes for underserved populations. Its diversified product lineup positions it as a significant contributor to specialized healthcare solutions.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
102
CEO
Mr. Joshua R. Disbrow
Country
United States
IPO Year
2008
Website
aytubio.comAytu Biopharma Inc. (AYTU) Latest News & Analysis
Latest News
Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025
5 days ago
Quick Summary
Aytu BioPharma, Inc. (Nasdaq: AYTU) will report Q3 fiscal 2025 results on May 14, 2025, after market close, with a conference call at 4:30 p.m. the same day.
Why It Matters
Aytu BioPharma's upcoming financial results and conference call can affect stock performance, influencing investor sentiment and market valuation based on earnings and future guidance.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Aytu BioPharma, Inc. (Nasdaq: AYTU) will hold 1x1 meetings on April 24, 2025, and present at the Planet MicroCap Showcase on April 23, 2025, at 1:30 p.m. PT.
Why It Matters
Aytu BioPharma's upcoming meetings and presentation could signal potential growth opportunities and investor interest, impacting stock performance and market perception.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Aytu BioPharma, Inc. will hold its Q2 2025 earnings conference call on February 12, 2025, at 4:30 PM ET. Participants include CEO Josh Disbrow and CFO Ryan Selhorn.
Why It Matters
Aytu BioPharma's Q2 earnings call provides insights into financial performance and strategic direction, impacting stock valuation and investor sentiment. Key management participation signals potential developments.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Aytu BioPharma reported Q2 fiscal 2025 net income of $0.8M, adjusted EBITDA of $1.3M, and an 86% increase in Pediatric Portfolio revenue. The cash balance was $20.4M as of Dec 31, 2024.
Why It Matters
Aytu BioPharma shows strong growth with an 86% revenue increase and positive EBITDA, indicating operational improvement. The cash balance provides stability, appealing to investors.
Source: Accesswire
Market Sentiment:
Neutral
Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025
3 months ago
Quick Summary
Aytu BioPharma (NASDAQ: AYTU) will report Q2 fiscal 2025 results on February 12, 2025, after market close, followed by a conference call at 4:30 p.m. the same day.
Why It Matters
Aytu BioPharma's upcoming financial results and conference call may influence stock performance and investor sentiment, impacting trading strategies and portfolio decisions.
Source: Accesswire
Market Sentiment:
Neutral
Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
4 months ago
Quick Summary
Aytu BioPharma's CEO, Josh Disbrow, will participate in a webcast at the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025, at 10:00 a.m. ET.
Why It Matters
CEO participation in investor events can signal transparency and engagement, potentially influencing investor sentiment and stock performance for Aytu BioPharma.
Source: Accesswire
Market Sentiment:
Neutral
Frequently Asked Questions About AYTU Stock
What is Aytu Biopharma Inc.'s (AYTU) stock forecast for 2025?
Based on our analysis of 4 Wall Street analysts, Aytu Biopharma Inc. (AYTU) has a median price target of $8.00. The highest price target is $8.00 and the lowest is $8.00.
Is AYTU stock a good investment in 2025?
According to current analyst ratings, AYTU has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.25. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AYTU stock?
Wall Street analysts predict AYTU stock could reach $8.00 in the next 12 months. This represents a 540.0% increase from the current price of $1.25. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Aytu Biopharma Inc.'s business model?
Aytu Biopharma generates revenue by producing and commercializing a diverse range of prescription therapeutics, primarily targeting pediatric conditions and other niche markets like urology and orthopedics. The company invests in clinical trials to enhance its product pipeline and engages in strategic partnerships and acquisitions to expand its market presence.
What is the highest forecasted price for AYTU Aytu Biopharma Inc.?
The highest price target for AYTU is $8.00 from at , which represents a 540.0% increase from the current price of $1.25.
What is the lowest forecasted price for AYTU Aytu Biopharma Inc.?
The lowest price target for AYTU is $8.00 from at , which represents a 540.0% increase from the current price of $1.25.
What is the overall AYTU consensus from analysts for Aytu Biopharma Inc.?
The overall analyst consensus for AYTU is bullish. Out of 4 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $8.00.
How accurate are AYTU stock price projections?
Stock price projections, including those for Aytu Biopharma Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 12, 2025 2:31 AM UTC